The Outcomes of Treating New Tuberculosis Patients in Community Hospitals Using 2IRZE/4IR versus 2IRE/7IR Regimen
The Outcomes of Treating New Tuberculosis Patients Using 2IRZE/4IR versus 2IRE/7IR Regimen
Keywords:
tuberculosis patients, treatment outcomes, TB drug regimenAbstract
Tuberculosis (TB) is a major global public health problem. Thailand is among countries with a high TB burden. This analytical study aimed to assess treatment effect of new TB patients admitted to community hospitals in Lamphun Province between the 2IRZE/4R and 2IRE/7IR regimens. Data were recruited during 1 October 2017–31 October 2022, 453 people and collected from medical records, the TBCM program and the Hos-XP program. Data were compared between groups using Chi-square, Fisher's exact, Independent t, and Mann-Whitney U tests. The results showed that 418 (92.3%) of TB patients received the 2IRZE/4IR regimen and 35 (7.7%) received the 2IRE/7IR regimen. Among the 2IRZE/4IR and 2IRE/7IR regimens, TB patients were 329 (78.4%) and 26 (74.3%) males, respectively (p = 0.542), aged 35-64 years, 210 people (52.6%) and 18 people (51.4%), respectively (p = 0.477). Radiographs were found for pulmonary TB (TB M+) in 318 (76.1%) and 23 (65.7%) patients, respectively (p = 0.105). The results of success treatment were 371 patients (88.8%) and 32 patients (91.4%), respectively (p = 0.784). Thus, the two regimens were equally effective in treating TB. Therefore, the 2IRZE/4IR regimen is recommended as first-line therapy in TB patients and the 2IRE/7IR regimen is recommended when first-line adverse reactions occur or in patients at risk of developing hepatitis
References
World Health Organization. Global tuberculosis report 2021 [internet]. 2021 Jan [cited 2021 Oct 14]. Available from: URL: https://www.who.int/
Bureau of Tuberculosis, Department of Disease Control, Ministry of Public Health, Thailand. National tuberculosis control program guideline, Thailand 2021. Bangkok, Thailand: Aksorn Graphic and Design Publishing Limited Partnership; 2021.
Communicable Disease Control Group, Lamphun Provincial Public Health Office. NTRIP: Report on the results of the control and treatment of tuberculosis patients in Lamphun Province. 2018-2022 [internet]. 2022 Mar 4 [cited 2022 Sep 25]. Available from: URL: https://ntip-ddc.moph.go.th/uiform/Login.aspx
Wnanaphongsapak A, Moonfong K. Patients’ characteristic and factors related to causes of death in new pulmonary tuberculosis patients in Lamphun Province. Lanna Public Health J 2016;13(2):72-85.
Chi C, Leung M, Wing W, Yew M, Chi K, Chau B, et al. Tuberculosis in older people: a retrospective and comparative study from Hong Kong. J Am Geriatr Soc 2002;50(7):1219-26.
Sookya W, Inyaphong J. Factors associated with death during tuberculosis treatment among new patients with pulmonary tuberculosis in Health Region 10th. J Office DPC 10 Ubonratchathani. 2021;19(2):81-92.
Sirot J. Mortality and associated risk factors of pulmonary tuberculosis patients in Maha sarakham Hospital. Mahasarakham Hosp J 2021;18(2):88-96.
Boonsaen T, How important is body mass index?. [internet]. 2019 Jan 28 [cited 2023 Mar 2]. Available from: URL: https://www.si.mahidol.ac.th/th/healthdetail.asp?aid=1361
Krittiyanunt S, Sakulbamrungsil R, Wongwiwatthananukit S, Suthiputthanangoon W. Risk factors for hepatotoxicity from anti-tuberculosis drugs in Thai patients. Thai Pharmacy Health Sci J 2002;26(3-4):121-8.
Fongsiripaibu S, Yuenyong N, Kulkeratiyut S. Understanding and interpreting of preliminary laboratory results for annual health checkup. PTU J Sci Tech 2021;1(2):116-32.
Chang K, Leung C, Yew W. Lau T, Tam C. Hepatotoxicity of pyrazinamide. Am J Respir Crit Care Med 2008;177(12):1391-6.
Bao Y, Ma X, Rasmussen T, Zhong X. Genetic variations associated with anti-tuberculosis drug-induced liver injury. Curr Pharmacol Rep 2018;4(3):171–81.
Bernuau J, Durand F, Pessayre D, Didier S, Belaiche J, Degott C et al. Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid. Hepatology 1995;21(4):929-32.
Shih T, Pai C, Yang P, Chang W, Wang N, Hu O. Novel mechanism underlies the hepatotoxicity of pyrazinamide. Antimicrob Agents Chemother 2013;57(4):1685–90.
Wada M, Yoshiyama T, Ogata H, Ito K, Mizutani S, Sugita H. Six-months chemotherapy (2HRZS or E/4HRE) of new cases of pulmonary tuberculosis-six-year experiences on its effectiveness, toxicity, and acceptability. Kekkaku 1999;74(4):353-60.
Shin H, Kwon Y. Treatment of drug susceptible pulmonary tuberculosis. Tuberc Respir Dis 2015;(78):161-7.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Buddhchinaraj Phisanulok Hospital
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
